Skip to main content
. Author manuscript; available in PMC: 2019 Mar 15.
Published in final edited form as: Cancer. 2017 Dec 6;124(6):1197–1206. doi: 10.1002/cncr.31178

Figure 4.

Figure 4

Step-by-step prostate cancer mortality rate ratios and simulation-based uncertainty ranges for the Erasmus-MISCAN and FHCRC models. The changes in the models are cumulative. In run 13 a cure parameter of 0 is used, in all other runs, the ERSPC-based cure parameter is used (0.22 for Erasmus-MISCAN, 0.18 for FHCRC). Supplementary Material 9 provides intervals that incorporate variability in the estimated cure rate parameter (FHCRC model). For each run 0-13, 100 simulations of a single ERSPC or PLCO trial population were performed to generate sample mortality rate ratios; the bracketed line (uncertainty range) and dot represent, respectively, the range and mean of the sample mortality rate ratios observed over the 100 simulations.

In run 0-5 a follow-up of 11 years is used, in run 6-13 the follow-up is 13 years. In each step the listed implementation change is added to the previous step.